Clinical Trials Logo

Pulmonary Embolism clinical trials

View clinical trials related to Pulmonary Embolism.

Filter by:

NCT ID: NCT02029456 Recruiting - Pulmonary Embolism Clinical Trials

Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism

Start date: June 2011
Phase: Phase 4
Study type: Interventional

The aim of the present study was to assess the effects of low-dose (25mg) prolonged administration (in 6 hours) of tissue type plasminogen activator (tPA) on in-hospital mortality and outcomes in patients with massive PE.

NCT ID: NCT01975090 Completed - Pulmonary Embolism Clinical Trials

The SENTRY Clinical Study

SENTRY
Start date: September 2014
Phase: N/A
Study type: Interventional

The SENTRY Bioconvertible Inferior Vena Cava (IVC) Filter has been developed to provide temporary protection against pulmonary embolism (PE).

NCT ID: NCT01961141 Withdrawn - Pneumonia Clinical Trials

Evaluation of Lung Doppler Signals in Patients Presenting to EMD

Start date: November 2014
Phase: N/A
Study type: Observational

Historically, ultrasound has been unable to provide interpretable data from the lung parenchyma, mainly because of the high total ultrasound energy attenuation and scattering by the air in the lungs. Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package (transthoracic parametric Doppler, TPD, EchoSense Ltd., Haifa, Israel). These lung Doppler signals (LDS) are in full synchrony with the cardiac cycle and can be obtained from the lungs, including areas remote from the heart and main pulmonary vessels. The LDS waves typically have peak velocities of up to 30 cm/s and are of relatively high power, making it possible to detect them despite the aforementioned attenuation by the air in the lungs. The LDS are thought to represent the radial wall movement of small pulmonary blood vessels, caused by pressure pulse waves of cardiac origin which propagate throughout the lung vasculature. The LDS may contain information of significant diagnostic and physiological value regarding the pulmonary parenchyma and vasculature, as well as the cardio-vascular system in general. Preliminary data from ongoing studies employing the TPD in chronic diseases such as CHF, COPD and pulmonary hypertension, show promise regarding the diagnostic potential of the lung Doppler signals (unpublished data). However, lung Doppler signals in acute disease states were not investigated so far. It is reasonable to speculate that the pathological processes underlying acute cardiovascular and pulmonary diseases will affect the LDS. Therefore, the TPD may have diagnostic potential in these conditions. For example, during acute pulmonary embolism a portion of the pulmonary vascular system is occluded; therefore it's reasonable to assume that the LDS will disappear in the affected area, enabling to confirm the diagnosis without using ionizing radiation (as in CT or lung scan). Another example is COPD exacerbation, during which there is usually air trapping in the lungs; thus, the LDS may be attenuated by the increase of air volume in the lungs.

NCT ID: NCT01947998 Completed - Atrial Fibrillation Clinical Trials

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Start date: December 22, 2011
Phase:
Study type: Observational

This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.

NCT ID: NCT01947985 Completed - Atrial Fibrillation Clinical Trials

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Start date: February 1, 2012
Phase:
Study type: Observational

This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.

NCT ID: NCT01947959 Completed - Atrial Fibrillation Clinical Trials

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Start date: December 22, 2011
Phase:
Study type: Observational

This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.

NCT ID: NCT01939301 Completed - Pulmonary Embolism Clinical Trials

Nitric Oxide to Treat Pulmonary Embolism

Start date: October 2013
Phase: Phase 2
Study type: Interventional

This is a randomized study to treat subjects diagnosed with pulmonary embolism with inhaled nitric oxide or placebo (oxygen).

NCT ID: NCT01935141 Withdrawn - Clinical trials for Multiple Pulmonary Emboli

Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli

Start date: January 2016
Phase: N/A
Study type: Interventional

With the improvement in CT scanners and injectors, diagnostic chest CT can now be performed in less than 10 seconds. It was hypothesized that diagnostic CT pulmonary angiograms could be done with less than the usual 80-120 ml of contrast used. We have developed a method of performing diagnostic CT pulmonary angiograms with 30 ml of intravenous contrast in most patients. The long-term objective of this study is to show that there is no difference in the diagnostic efficacy of this low dose 30 ml technique when compared to the more traditional full-dose technique.

NCT ID: NCT01908231 Completed - Pulmonary Embolism Clinical Trials

Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism

TELOS
Start date: December 2012
Phase: N/A
Study type: Observational

To prospectively investigate the association between plasma lactate concentration and short-term adverse outcomes in patients with acute PE.

NCT ID: NCT01899339 Completed - Clinical trials for Submassive Pulmonary Embolism

Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis

SPEAR
Start date: May 2013
Phase:
Study type: Observational

Patients with Submassive Pulmonary Embolism treated with ultra-sound therapy will have an improved right ventricular function 72 hours post treatment.